
Stability

Christopher A Bravery

cbravery@advbiols.com

1



Consulting on Advanced Biologicals

Overview

- Issues I see with Stability Studies (cell therapy)
- How its expected to be done (ICH principles)
 - Stress testing
 - Accelerated stability
 - Real-time stability
 - In-use stability
 - Other related studies (not discussed)

2



Consulting on Advanced Biologicals

CBMP – Do these Stability Data Look Suitable?

Real-time stability 4 °C; Batch #1234.

Overall WEAK specification

Necessary but don't evaluate stability?

How can this be useful?

Is this assay sensitive to change?

Is this taking up too much of the DP?

Too few time-points

What does this really tell you?

Attribute	Test method	Specification	Time-point		
			0	1	2
Appearance	Visual inspection	red/orange turbid solution	complies	complies	complies
Identity	Phenotypic marker (flow cytometry)	complies	complies	complies	complies
Viability	Trypan blue (manual count)	≥ 70%	95	94	92
Potency	Bioassay	≥ 4 U/10 ⁶ cells	12.1	9.8	6.8
Sterility	EP/USP	No growth	No growth	NT	No growth

3



Consulting on Advanced Biologicals

CBMP – Better?

Now viability can be interpreted

Viability fairly stable

Nearly 50% of cells lost

Attribute	Test method	Specification	Time-point		
			0	1	2
Appearance	Visual inspection	red/orange turbid solution	complies	complies	complies
Identity	Phenotypic marker (flow cytometry)	complies	complies	complies	complies
Viability	Trypan blue (manual count)	≥ 70%	95	94	92
Content	Manual cell count	≥ 10 ⁶ cells/mL	2.1 × 10 ⁶	1.8 × 10 ⁶	1.1 × 10 ⁶
Potency	Bioassay	≥ 4 U/10 ⁶ cells	12.1	9.8	6.8
Sterility	EP/USP	No growth	No growth	NT	No growth

- Presenting viability as a percentage without total cells is meaningless.
 - Yet I see this often?

4



Consulting on Advanced Biologicals

CBMP – Different ways to present data

Attribute	Test method	Specification	Time-point		
			0	1	2
Appearance	Visual inspection	red/orange turbid solution	complies	complies	complies
Identity Purity	Phenotypic marker (flow cytometry)	complies >80 %	complies 95%	complies 93%	complies 94%
Viability	Trypan blue (manual count)	≥70%	95	94	92
Non-viable cells	Trypan blue (manual count)	≤ 0.3 × 10 ⁶ non-viable cells/mL	0.1 × 10 ⁶	0.1 × 10 ⁶	0.1 × 10 ⁶
Content	Manual cell count	≥ 10 ⁶ cells/mL	2.1 × 10 ⁶	1.8 × 10 ⁶	1.4 × 10 ⁶
Content	Manual cell count	≥ 10 ⁶ viable cells/mL	2.0 × 10 ⁶	1.7 × 10 ⁶	1.0 × 10 ⁶
Potency	Bioassay	≥ 4 U/10 ⁶ cells	12.1	9.8	6.8
Sterility	EPI/USP	No growth	No growth	NT	No growth

Product-related Impurity

A measure of purity unlike identity is quantitative and likely to be stability-indicating.

Total cell content could be total cells or total viable cells.

- Note: this is not a recommendation, merely to make the point that you need to consider the best way to present data.

6



Consulting on Advanced Biologicals

Take-Home Message What Are You Trying to Measure?

- Measurement:** process of experimentally obtaining one or more quantity values that can reasonably be attributed to a quantity.
- Analyte:** specific substance to be measured (e.g. IL-2, haemoglobin).
- Measurand:** quantity to be measured

12 Focus – Advanced therapies

Measurement reliability over the cellular therapeutic product lifecycle

Author: Christopher A Bravery, Consulting on Advanced Biologicals Ltd, London, UK.

What are reference materials? In metrology all measurements are made with respect to a reference. For example the amount of protein in a vial will be defined in mg units per unit volume (mg/mL). Development of test kits in a common test, yet how often have you stopped to question why you are applying and, importantly, why you are applying a reference material to the test method? The literature, absence of a universal test kit, and the lack of a common test kit.

Regulatory Rapporteur – Vol 12, No 5, May 2015

See discussion in these

Cytotherapy 2014, 0: 1–10
Cytotherapy 16(9): 1187–1196.

International Society for Cellular Therapy ISCT

Reference materials for cellular therapeutics

CHRISTOPHER A. BRAVERY¹ & ANNA FRENCH²

¹Consulting on Advanced Biologicals Ltd, Advanced Biologicals Ltd, London, United Kingdom, and ²The Oxford–ECEL Centre for the Advancement of Sustainable Medical Innovation (EASMI), The University of Oxford, Oxford, United Kingdom.

Abstract
The development of cellular therapeutics (CTP) takes place over many years, and, when successful, the developer will anticipate the product to be in clinical use for decades. Successful demonstration of manufacturing and quality consistency is

6

ICH - General Principles

Specifics = case-by-case



7



<http://advbiols.com/documents/ICH.swf>

Consulting on Advanced Biologicals


Before undertaking any stability studies, you need to determine:

- ✓ what the **Stability-Indicating** parameters are
- ✓ the **most appropriate** analytical methods to evaluate these.
- ✓ The obvious way to do this is to deliberately 'degrade' the product (intermediate, DS etc).

8



Consulting on Advanced Biologicals



Identifying Stability-Indicating Parameters

Considerations-1

- Unlike (inert) proteins, cells are not in equilibrium with their environment (i.e. viable/alive/living).
 - Resistant to oxidation/reduction etc
 - protective mechanisms, repair mechanisms etc
 - How to identify changes leading up to (sudden?) loss of cell integrity/viability?
- Common viability methods (e.g. trypan blue) give only yes/no result for viability of each cell
 - explore earlier changes preceding loss of viability
 - e.g. apoptosis, autophagy, necrosis
 - Classification of cell death: *Cell Death Differ.* 2009 January ; 16(1): 3–11. doi:10.1038/cdd.2008.150.
 - Molecular definitions: *Cell Death and Differentiation* (2012) 19, 107–120

Identifying Stability-Indicating Parameters Considerations-2

- Measures of cell stress, e.g.
 - Biochemical
 - Physical (membrane integrity)
 - Secreted factors, e.g. heat-shock proteins etc.
- Receptor/ligand modulation
 - Surface receptor/ligands involved in the MoA may be induced, up/down-regulated, internalised/shed.
 - mRNA changes normally precede protein changes by hours to days.


11




Consulting on Advanced Biologicals

Sources of Analytical Error

Bravery & French; Cytotherapy 16(9): 1187-1196.



- Method needs to be 'sensitive to change'
- Sufficiently precise/accurate, robust etc.
- Such that can detect small changes in stability-indicating attributes.



12




gicals

Formulation Development

There should be studies to identify the optimal formulation


- Issue – off-the-shelf media are not optimised for your product and route of administration
- Data support justification for excipient specifications 3.2.P.4.4.



13



Real-Time and Accelerated Stability Studies



© 2016, Consulting on Advanced Biologicals Ltd

Note: The End of Shelf-life Specification should be in 3.2.S.4.1/P.5.1 (with Release Specification)

Accelerated Testing


“Studies designed to increase the rate of chemical degradation/ physical change of a substance by using exaggerated storage conditions as part of the formal stability studies. Data from these studies, in addition to long term stability studies, can be used to assess longer term chemical effects at non-accelerated conditions and to evaluate the effect of short term excursions outside the label storage conditions such as might occur during shipping. Results from accelerated testing studies are not always predictive of physical changes.”



onsulting on Advanced Biologicals

14

In-Use Stability (3.2.P.8)



Confirm the product is stable during clinical handling

- ✓ Thawing
- ✓ Reconstitution
- ✓ How soon
- ✓ Leave on side/put in fridge?

15



Consulting on Advanced Biologicals

Other Stability Studies

(Not discussed in this talk)

- Shipping
 - Shipping studies (real ± simulated) to evaluate impact on stability
- Raw materials
 - Where stability uncertain
 - Buffers, media, and other solutions prepared on-site
- QC samples
 - Duration of storage and handling before testing
 - Shipping to external tests labs

16



Consulting on Advanced Biologicals

Other Uses for Stability-Indicating Methods

- Extended characterisation
- **Comparability Studies**
 - Can be very useful because they are *sensitive to change*
 - for *extended characterisation* (i.e. beyond routine testing)
 - as well as stability studies undertaken as part of comparability.

17



Consulting on Advanced Biologicals

Conclusions 1/2

Before a stability specification and tests protocol can be devised;

- Need to understand the stability-indicating profile (including stability-indicating parameters)
 - General characterisation
 - Stress-testing
- Need to identify stability-indicating methods (to measure stability-indicating parameters)
 - Sensitive to change
 - Sufficiently precise, (accurate), robust etc.
- These data will be needed to set and justify your stability specification and acceptance criteria.

18



Consulting on Advanced Biologicals

Conclusions 2/2

- Overall testing can be reduced in some instances by the use of Bracketing and/or Matrixing
 - Warning: use appropriately
- Release and Stability specifications and acceptance criteria can differ
 - Not all release tests are stability-indicating
 - e.g. process-related impurities unlikely to change
 - It may be necessary to accept some parameters change gradually over the shelf-life;
 - Stability (end of shelf-life) > Release
 - Needs justification, e.g. toxicity data (safe levels)
 - e.g. viability for fresh cell products.